A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.

Atakan Topcu Ayse Irem Yasin Abdallah T M ShbairMehmet BesirogluMelih SimsekZehra SucuogluIsmail YurtseverZuhal GucinMesut SekerHaci Mehmet Turk

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.

Keyphrases

systematic review
ultrasound guided
healthcare
fine needle aspiration
emergency department
stem cells
liver failure
metabolic syndrome
adipose tissue
drug induced
polycystic ovary syndrome
adverse drug
combination therapy
replacement therapy
chemotherapy induced